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doi:10.1Objective: It is hypothesized that an altered turnover of extracellular matrix mediated by matrix metalloprotei-
nases (MMPs) is present in thoracic aortic aneurysms. Here, we analyzed the occurrence of MMPs and MMP
inhibitors in ascending aortic aneurysms in patients with bicuspid and tricuspid aortic valves.
Methods: Expression of 23 MMPs and their inhibitors was measured in aortic intima/media and adventitia in
109 patients (40 tricuspid, 69 bicuspid, 68 with aortic diameter  4.5 cm, and 41 with 4.0 cm) using Affyme-
trix Exon arrays (Affymetrix, Santa Clara, Calif). Gene expression was confirmed by quantitative real-time poly-
merase chain reaction. Principal components analysis was used to study differences in gene expression.
Immunohistochemistry was used to study protein expression.
Results:We detected messenger RNA expression for gelatinases (MMP2 and MMP9), stromelysin 3 (MMP11),
all membrane bound MMPs (MMP14, MMP15, MMP16, MMP17, MMP24, MMP25), MMP19, MMP21, and
MMP28 in ascending aorta. No expression of collagenases was detected. Principal components analysis showed
that changes in mRNA expression between dilated and nondilated aorta were mainly detected in patients with
tricuspid aortic valves. MMP14 andMMP19 showed higher expression in dilated aortas andMMP19 expression
correlated positively to maximal aortic diameter in patients with tricuspid aortic valves (Rho ¼ 0.61, P ¼ .004,
and Rho ¼ 0.57, P ¼ .008, using raw and body surface area–corrected aortic diameter, respectively). Immuno-
histochemical staining demonstrated increased medial expression of MMP14 and MMP19 in dilated aorta.
Conclusions: The present study identifies MMP14 and MMP19 as proteolytic enzymes potentially involved in
aneurysm formation in the ascending aorta of patients with tricuspid aortic valves. (J Thorac Cardiovasc Surg
2012;144:459-66)/B
SA bicuspid aortic valve (BAV) is present in 1% to 2% of the
population in theWestern world.1 The presence of BAV pre-
disposes for progressive dilatation of the ascending aorta
and thereby constitutes an increased risk for aortic aneu-
rysm and/or dissection.2 The etiology of the aortic dilatation
associated with BAV is still debated,3 and it has been
suggested that the dilatation is the result of altered hemody-
namic factors, that is, owing to abnormal valvular morpho-
logic and pathologic conditions.4 The idea of an intrinsic
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Tformation has also been put forward. In this context, prote-
olysis has been implicated as an important factor of the pro-
posed aortopathy. The main hypothesis is that an altered
turnover of extracellular matrix, mediated by matrix metal-
loproteinases (MMPs), is present in the aneurysmal aorta.5
Several different cell types have the capacity to express
MMPs, for example, endothelial cells, leukocytes, macro-
phages, fibroblasts, and vascular smooth muscle cells
(SMCs). There are more than 20 different known human
MMPs and 4 endogenous tissue inhibitors of metallopro-
teinases (TIMPs). The tissue distribution and function of
several of these enzymes are known to only a limited ex-
tent,6 but some clues as to what role MMPs and TIMPs
may play in formation of thoracic aortic aneurysm
(TAAs) has been presented. Previous work has mainly
shown that increased expression of MMP2 and no signif-
icant alterations in MMP9, TIMP1, and TIMP2 expres-
sion is evident in TAA associated with BAV, but the
results are conflicting. Some investigators have also pos-
itively correlated increased MMP2 expression in BAV pa-
tients to aortic diameter.7,8
The underlying molecular mechanisms of TAA forma-
tion in patients with bicuspid or tricuspid aortic valves
(TAVs) are complex. This study analyzed the occurrence
of all known MMPs, together capable of degrading allrdiovascular Surgery c Volume 144, Number 2 459
Abbreviations and Acronyms
BAV ¼ bicuspid aortic valve
MMP ¼ matrix metalloproteinase
mRNA ¼ messenger ribonucleic acid
PC ¼ principal component
PCA ¼ principal components analysis
PCR ¼ polymerase chain reaction
RNA ¼ ribonucleic acid
SMC ¼ smooth muscle cell
TAA ¼ thoracic aortic aneurysm
TAV ¼ tricuspid aortic valve
TIMP ¼ tissue inhibitors of metalloproteinase
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Scomponents of the extracellular matrix, in ascending aortic
aneurysms associated with BAVor TAV.METHODS
Patients
The study population consisted of 109 patients with disease of the aortic
valve and/or aorta who underwent open cardiac operations at the Cardio-
thoracic Surgery Unit at the Karolinska University Hospital, 2007 to
2009. The patients were divided into groups depending on valvular mor-
phologic status and disease of the ascending aorta (TAV, n ¼ 40; BAV,
n ¼ 69; dilated aorta, n ¼ 68; nondilated aorta, n ¼ 41) (Table 1). The as-
cending aorta was considered to be nondilated at a diameter of 4.0 cm or
less and dilated at a diameter of 4.5 cm or more; subjects with aortic dimen-
sions of 4.1 to 4.4 cm were not included in the analyses. Patients who were
found to have concomitant significant coronary artery disease at the time of
inclusion were excluded from the study. The study was approved by the lo-
cal ethics committee and patient informed consent was obtained.
Ribonucleic Acid (RNA) Isolation
Biopsy tissue was taken from the anterior (convex) part of the aorta, that
is, the site of the aortotomy a few centimeters above the aortic valve. The
tissue was separated into intima/media and adventitia by adventicectomy.
Total RNAwas isolated using Trizol (GIBCO-BRLLife Technologies, Gai-
thersburg, Md) and RNeasy Mini kit (Qiagen, Crawley, United Kingdom)TABLE 1. Patient demographics
Aortic diameter
TAV
40 mm
N 17
Gender, No. of women 5
Age (y), mean  SD 69  11
BSA (m2mean  SD 1.99  0.19
Max aortic diameter (mm) 33.7  3.9
Mean  SD (min, max) (27.5, 39.8)
Max aortic diameter/BSA (mm/m2) 17  2
AS 12
AR 5
Normal aortic valve 0
Values are presented as mean  standard deviation (SD) or frequency. TAV, Tricuspid aort
aortic regurgitation. Nondilated versus dilated aorta: *P ¼ .04. yP<.0001. zValvular path
P ¼ .03.
460 The Journal of Thoracic and Cardiovascular Surgincluding treatment with RNase-free DNase set (Qiagen) according to
manufacturer’s instructions. The quality of RNAwas analyzed with an Agi-
lent 2100 bioanalyzer (Agilent, Santa Clara, Calif) and quantity was mea-
sured by a NanoDrop (Thermo Scientific, Waltham, Mass).
Gene Arrays
The RNA samples were hybridized and scanned at the Karolinska Insti-
tutet microarray core facility. Affymetrix GeneChip Human Exon 1.0 ST
arrays and protocols were used (Affymetrix, Santa Clara, Calif). The raw
Cel files were preprocessed and log2 transformed using Robust Multichip
Average normalization as implemented in the Affymetrix Power Tools
1.10.2 package apt-probeset-summarize. All investigations were done on
the core sets of meta probes provided by Affymetrix. Cutoff level for
gene expression was defined at 4.5, which was the level below which
most Y-chromosome genes were found in female arrays.
Real-time Polymerase Chain Reaction (PCR)
Samples were analyzed in duplicates and evaluated with a standard
curve using TaqMan Gene Expression Assay (Applied Biosystems, Carls-
bad, Calif) using the following assays: MMP1 (Hs00233958), MMP2
(Hs00234422), MMP3 (Hs00233962), MMP7 (Hs00159163), MMP9
(Hs00957562), MMP12 (Hs00159178), MMP13 (Hs00233992), MMP14
(Hs00237119), MMP19 (Hs00275699), MMP21 (Hs01040378), MMP25
(Hs00360851), TIMP2 (Hs00234278), and TIMP4 (Hs00162784). The Ri-
bosomal Protein Large P0 (RPLP0) (Hs99999902) was used as a house-
keeping gene.
Immunohistochemistry
Aortic specimens were fixated in 4% zinc formaldehyde (Histolab AB,
Gothenburg, Sweden) and embedded in paraffin. Sections 5-mm thick were
pretreated with DIVA decloaker 103 solution (Biocare Medical, Concord,
Calif). Primary antibodies were rabbit monoclonal to MMP14 (1:25; Ab-
cam, Cambridge, United Kingdom), rabbit polyclonal to MMP19 (1:100;
Abcam, Cambridge, United Kingdom), mousemonoclonal to alpha smooth
muscle actin (1:5000; Sigma-Aldrich, St Louis, Mo), mouse monoclonal to
CD68 (1:100; Novocastra, Leica Microsystems, Wetzlar, Germany), and
mouse monoclonal to von Willenbrand factor (1:5000; DAKO, Glostrup,
Denmark).
Statistical Analysis
The statistical analysis was performed using Statview software (SAS In-
stitute, Inc, Cary, NC). The Mann-Whitney U test was used for groupwise
comparisons and the Spearman rank correlation test for correlationsBAV
45 mm 40 mm 45 mm
23 24 45
9 5 10
61  15* 56  10 60  12
1.97  0.25 1.99  0.21 2.02  0.20
53.8  7.6y 36.1  3.1 50.3  3.3y
(45.0, 70.0) (30.2, 39.9) (45.1, 57.1)
28  7y 18  2 25  3y
1z 13 20z
18 11 14
4 0 11
ic valve; BAV, bicuspid aortic valve; BSA, body surface area; AS, aortic stenosis; AR,
ology (AS vs AR vs normal) in nondilated versus dilated aorta: TAV P<.0001; BAV
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mean with standard deviation or median with interquartile range when
applicable.
In addition, principal components analysis (PCA) was performed on Af-
fymetrix Human Exon 1.0 STArray meta probe set level data that had been
preprocessed using Robust Multichip Average normalization. Before PCA,
the data were scaled to unit variance and mean centered. In the intima/me-
dia analysis, the first 3 principal components (PCs) were enough (according
to cross-validation) to describe 63%, 64%, and 67% of the variance (Rx
2)
in the TAV and BAV together, TAV separately, and BAV separately data
sets, respectively. The Qx
2 (cumulative fraction of the total variation of
X that can be predicted by the model) parameter for the 3 models is accord-
ing to the following: TAV and BAV together, 0.33; TAV separately, 0.24;
and BAV separately, 0.36. Multivariate model quality parameters for ad-
ventitia models after 3 PCs are according to the following: TAV separately,
Rx
2 ¼ 0.66, Qx2 ¼ 0.049; BAV separately, Rx2 ¼ 0.64, Qx2 ¼ 0.30. PCA
was performed using the SIMCAPþ12.0.1364 (Umetrics, Umea, Sweden)
software. The tolerance ellipsoid/ellipse based onHotelling’s T2 at a signif-
icance level of .05 is calculated and shown in the score plots.
RESULTS
No mRNA Expression of Collagenases Detected in
Ascending Aortic Wall
We detected mRNA expression for gelatinases (MMP2
and MMP9), stromelysin 3 (MMP11), all membrane-
bound MMPs (MMP14, MMP15, MMP16, MMP17,
MMP24, and MMP25) and for MMP19, MMP21, and
MMP28 in the intima/media section of nondilated aorta in
patients with BAVand TAV (Table 2). There were no differ-
ences in mRNA expression in nondilated aorta between
BAVand TAV patients (data not shown). No mRNA expres-
sion of the collagenases (MMP1, MMP8, and MMP13)
could be detected. Furthermore, TIMP1 to TIMP4 were
all expressed at levels above background (Table 2). The
same expression pattern of MMPs and TIMPs was detected
in both the intimal/medial (Table 2) and the adventitialTABLE 2. Log2 mRNA expression levels in intima/media of non-dilated a
TAV
Nondilated
TAV
Dilated
TAV
P valu
MMP2 10.06  0.54 (9.20, 10.90) 10.13  1.00 (9.14, 11.24) >.2
MMP9 6.00  0.51 (5.37, 7.03) 6.09  0.63 (5.45, 9.22) >.2
MMP11 6.24  0.38 (5.75, 6.69) 6.35  0.22 (6.08, 7.32) .18
MMP14 7.99  0.39 (7.32, 8.53) 8.49  0.60 (7.68, 9.15) <.001
MMP15 6.16  0.29 (5.55, 6.57) 5.97  0.28 (5.72, 6.37) .10
MMP16 7.62  0.47 (7.06, 8.88) 7.50  0.92 (4.74, 9.01) >.2
MMP17 6.07  0.48 (5.39, 6.52) 5.94  0.32 (5.51, 6.28) .022
MMP19 5.60  0.41 (4.97, 6.28) 5.90  0.49 (5.52, 7.34) .001
MMP21 5.08  0.36 (4.51, 5.48) 4.83  0.17 (4.64, 5.13) .008
MMP24 5.39  0.42 (4.77, 5.65) 5.10  0.21 (4.86, 5.50) .054
MMP25 6.03  0.41 (5.45, 6.40) 5.80  0.24 (5.55, 6.17) .019
MMP28 6.27  0.42 (5.70, 6.52) 6.03  0.25 (5.62, 6.37) .028
TIMP1 11.95  0.51 (11.51, 12.87) 11.82  0.69 (11.14, 13.29) >.2
TIMP2 11.25  0.32 (10.41, 12.01) 11.58  0.47 (11.13, 12.09) .007
TIMP3 8.38  1.19 (7.76, 10.09) 8.99  0.67 (8.18, 10.73) .18
TIMP4 7.18  1.00 (6.48, 8.71) 6.58  0.62 (5.88, 8.21) <.001
Values are presented as median interquartile range and minimum, maximum.mRNA, Me
matrix metalloproteinases; TIMP, tissue inhibitor of matrix metalloproteinases.
The Journal of Thoracic and Calayers of dilated aortic specimens (data not shown). To con-
firm the expression measurements of the exon arrays, we
performed real-time PCR for a subset of MMPs and TIMPs.
The results of the 2 different experimental methods were
compared, and positive correlations were found between
the results from the exon array analysis and the results of
the real-time PCR analysis for all the MMPs tested except
for MMP25 (TAV: MMP2 Rho 0.84, P < .001; MMP9
Rho 0.72, P<.001; MMP14 Rho 0.84, P<.001; MMP19
Rho 0.57, P ¼ .009; MMP25 Rho 0.27, P> .2; TIMP2
Rho 0.75, P<.001; TIMP4 Rho 0.90, P<.001). MMP25
had expression levels just above our defined threshold in
microarray measurements and similar low expression levels
(cycle threshold values of 36) when analyzed with real-time
PCR. Furthermore, the low mRNA expression of MMP1,
MMP3, MMP7, MMP12, andMMP13 was confirmed using
real-time PCR (mean cycle threshold values of 36, 36, 33,
33, and 31, respectively).TheGene Expression Pattern ofMMPs and TIMPs in
Ascending Aorta Differs According to Valvular
Structure and Aortic Disease
A PCA based on the expression of the identified MMPs
and TIMPs in intima/media showed no separation of pa-
tients with dilated aortas from patients with nondilated aor-
tas when analyzing BAV and TAV patients together
(Figure 1, A) nor when analyzing BAV patients separately
(Figure 1, C). However, TAV patients with dilated aortas
could be separated from patients with nondilated aortas
(Figure 1, B). This suggests that differences in mRNA ex-
pression of MMPs and TIMPs, in the intimal/medial layer,
between dilated and nondilated aortas are mainly confinednd dilated ascending aorta
e
BAV
Nondilated
BAV
Dilated
BAV
P value
10.14  0.45 (9.15, 10.99) 10.34  0.66 (8.54, 11.30) .12
5.83  0.21 (5.63, 6.78) 5.83  0.28 (5.57, 6.34) >.2
6.26  0.34 (5.84, 6.77) 6.14  0.33 (5.51, 6.61) >.2
8.01  0.51 (7.32, 8.78) 8.31  0.48 (6.52, 8.90) .009
5.93  0.44 (5.55, 6.54) 5.97  0.22 (5.55, 6.36) >.2
7.91  0.80 (6.54, 8.87) 7.81  0.58 (6.71, 8.97) >.2
6.04  0.56 (5.29, 6.55) 5.93  0.38 (5.45, 6.45) >.2
5.57  0.51 (5.03, 6.15) 5.79  0.37 (5.23, 6.35) .010
4.88  0.41 (4.69, 5.57) 4.91  0.27 (4.63, 5.49) >.2
5.19  0.37 (4.75, 5.76) 5.20  0.32 (4.83, 5.66) >.2
5.83  0.40 (5.17, 6.42) 5.80  0.23 (5.43, 6.19) >.2
6.12  0.30 (5.82, 6.52) 6.11  0.29 (5.59, 6.53) >.2
11.73  0.63 (10.82, 12.42) 11.70  0.48 (10.19, 12.42) >.2
11.32  0.52 (10.60, 12.12) 11.76  0.61 (9.84, 12.35) .001
9.23  0.76 (8.05, 10.12) 9.10  0.44 (7.35, 10.26) >.2
7.13  0.85 (6.12, 9.03) 6.96  0.75 (5.93, 8.40) >.2
ssenger ribonucleic acid; TAV, tricuspid aortic valve; BAV, bicuspid aortic valve;MMP,
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FIGURE 1. PCA of Affymetrix Human Exon 1.0 STArray meta probe set
level data of 12 MMP and 4 TIMP genes expressed in aortic samples from
109 patients. Three-dimensional score plots showing PC 1 to PC 3 plane of
nondilated (black) and dilated (red) aortic samples, BAVand TAV together
(A), TAV (B), and BAV (C). A PCA, in this case, is a projection to 3
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Sto TAV patients. Figure 2, A, shows that the dilated aortas
(red dots) of TAV patients are forming a cluster in the lower
right quadrant of the multivariate score plot in the direction
of first PC. PC 1 is thus responsible for separating dilated
from nondilated aortic tissue. The genes responsible for
this clustering of patients can be found in the lower right
quadrant of the multivariate loading plot (MMP14,
MMP19, MMP9, and TIMP3, Figure 2, B).
The same analysis was also performed on samples from
adventitia giving rise to a good model in BAV, but the sep-
aration between dilated and nondilated tissue was not clear.
The multivariate model in TAV, however, was not satisfying
(Qx
2 ¼ 0.049), thereby showing no separation between di-
lated and nondilated tissue (analysis not shown).
Univariate analyses of differences in MMP and TIMP
mRNA expression in the intima/media of TAV patients
showed higher expression levels of MMP14, MMP19, and
TIMP2 in dilated versus nondilated aortas (Table 2). In con-
trast, MMP17, MMP21, MMP25, MMP28, and TIMP4 all
showed lower expression levels in dilated aortas in TAV pa-
tients. In BAV patients, MMP14, MMP19, and TIMP2 also
showed higher expression levels in dilated aortas (Table 2).
None of the MMPs or TIMPs was found to have lower ex-
pression levels in BAV patients with dilated versus nondi-
lated aortas. There was no difference in MMP9 and
TIMP3 expression in the intima/media section comparing
dilated and nondilated aortas in TAV and BAV patients
(Table 2).
To further analyze the intima/media of TAV patients with
dilated aortas, we performed correlation analyses of MMP
expression levels and maximal ascending aortic diameter
measured 4 cm above the aortic valve. Of the MMPs that
showed higher expression levels in TAV patients with di-
lated aortas, MMP19 correlated positively to maximal aor-
tic diameter (Rho 0.61, P ¼ .004, and Rho 0.57, P ¼ .008
for raw and BSA-indexed values, respectively). MMP14
showed borderline significance for raw values (Rho 0.40,
P ¼ .063) but did not correlate to BSA-indexed values
(Rho 0.12, P>.2). TIMP2 did not correlate to aortic diam-
eter (Rho 0.26, P¼ .23, and Rho 0.02, P>.2). Of theMMPs
and TIMPs that showed lower expression levels in TAV
patients with dilated aortas, only TIMP4 correlated nega-
tively to raw values (Rho 0.49, P ¼ .021) whereas
MMP25, MMP28 and TIMP4 correlated negatively to
BSA-indexed values (Rho 0.45, P ¼ .036, Rho 0.43,dimensions from 16 variables that are composed of the gene expression
levels of the MMPs included in the study. Each patient will thereby be rep-
resented by a point in a 3-dimensional PC plane that summarizes the orig-
inal 16 dimensional properties of the particular patient. PCA, Principal
components analysis; PC, principal component; BAV, bicuspid aortic valve;
TAV, tricuspid aortic valve; MMP, matrix metalloproteinase; TIMP, tissue
inhibitors of metalloproteinase.
ery c August 2012
FIGURE 2. PCA of Affymetrix Human Exon 1.0 STArray meta probe set
level data of 12 MMP and 4 TIMP genes expressed in aortic samples from
40 patients with TAV. A, PC score plot showing nondilated (black) and di-
lated (red) aortic samples. B, Loading PC plot showing the corresponding
genes (black dots) on meta probe set level. The loading plot shows which
genes are responsible for clustering of the patients in the score plot. PCA,
Principal components analysis; PC, principal component; TAV, tricuspid
aortic valve; MMP, matrix metalloproteinase; TIMP, tissue inhibitors of
metalloproteinase.
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SP¼ .046, and Rho0.55, P¼ .010, respectively). In adven-
titia, MMP14 and MMP19 expression did not correlate
to maximal aortic diameter in TAV patients (Rho0.039,
P>.2, and Rho 0.16, P>.2, respectively, data not shown).
In BAV patients, MMP14, MMP19, and TIMP2 expression
did not correlate to either rawmaximal aortic diameter (Rho
0.008, P> .2, Rho0.27, P> .2, and Rho 0.20, P> .2,The Journal of Thoracic and Carespectively) or BSA-indexed values (Rho0.13, P> .2,
Rho0.20, P ¼ .20, and Rho 0.12, P>.2, respectively).
MMP14 and MMP19 Protein Expression Is
Upregulated in the Medial Layer of Dilated Aorta
Immunohistochemistry was used to localize the expres-
sion of MMP14 and MMP19 in aortic wall of TAV patients.
The analysis showed that MMP19 protein was expressed
mainly by endothelial cells (cells expressing von Wille-
brand factor) in patients with nondilated aortas (Figure 3).
In dilated aortas, the endothelial expression was still pres-
ent, but a strong MMP19 expression was also evident in
the medial layer. Similar to MMP19, MMP14 protein ex-
pression was upregulated in the media of dilated aortas.
DISCUSSION
This study analyzed the mRNA expression of all known
members of the MMP family in the ascending aortic wall
to characterize protease expression in regard to valvular
and aortic morphology. PCA of mRNA expression sug-
gested that a change in MMP expression profile is espe-
cially pertinent in TAV patients with dilated aortas as
compared with TAV patients with nondilated aortas. Fur-
thermore, our study identified MMP14 and MMP19 as
potentially important factors in the pathogenesis of TAA
when TAV is present. The mRNA expression of MMP19
correlated with aortic diameter in TAV patients but not
in BAV patients. Our data are in agreement with previous
findings suggesting that the underlying mechanisms of
BAV-associated TAA differs from TAV-associated
TAA.9,10 Furthermore, we found significant gene ex-
pression levels for gelatinases, MMP11, all membrane-
bound MMPs, and MMP19, MMP21, and MMP28. This
finding is different from what is found for abdominal aortic
aneurysms where MMP1, MMP2, MMP3, MMP8, MMP9,
MMP12, MMP13, and MMP14 are considered to consti-
tute the main contribution of the MMP family in aneurysm
formation.11
Our findings support the idea that the pathogenesis of
TAV- and BAV-associated TAA differs. When we were an-
alyzing the differences in mRNA expression levels between
dilated and nondilated aortas of TAV and BAV patients us-
ing a multivariate analysis, differences between the groups
were mainly detected in aortas from TAV patients. There
were no differences in mRNA expression between BAV
and TAV in nondilated aortas. We then proceeded with anal-
yses of the TAV group separate from the BAV group with
special reference to differences between nondilated aortas
and dilated aortas within the 2 groups. From this,
MMP14,MMP19, and TIMP2 stood out as possibly upregu-
lated in both TAV and BAV patients with dilated aortas,
whereas possibly downregulated MMPs were found only
in the TAV group. A correlation analysis between the
mRNA expression of MMP14, MMP19, TIMP2, andrdiovascular Surgery c Volume 144, Number 2 463
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tion of MMP19 to maximal aortic diameter, but once again
only in TAV patients. However, it should be stressed that the
ranges in aortic diameters were narrower in BAV than in
TAV patients, which could influence the analysis. The
PCA showed a separation of nondilated and dilated speci-
mens only in the TAV group, thus corroborating the results
from the 2 preceding analyses, that is, that the MMP and
TIMP profile in TAV patients with dilated aortas is likely
to be important to the pathogenesis of TAA in these patients.
MMP19 showed a higher expression level in dilated aor-
tas in comparison with nondilated aortas, and its expression
correlated with aortic diameter. MMP19 can hydrolyze
several matrix components such as collagen IV, laminin,
nidogen, tenascin, fibronectin, and gelatin.12 MMP19 ex-
pression has been found to be present in various normal tis-
sues with the exception of leukocytes.13 Our results confirm
previous findings by Kolb and associates14 ofMMP19 being
expressed in the media of blood vessels. Furthermore, Djo-
nov and colleagues15 have presented evidence of MMP19
expression in both SMCs and the endothelium in large
and medium-sized blood vessels.
MMP14 is in its substrate specificity similar to theMMPs
found to be important in abdominal aortic aneurysm forma-
tion, that is, the collagenases, matrilysins, and stromelysins,
and in this context is considered to promote the invasion of
inflammatory cells into the aortic wall.11,16 However,
similar to MMP19, the immunohistochemical analyses
clearly showed that MMP14 protein expression was
mainly upregulated in the medial layer of the dilated
aorta, a region consisting of SMCs/myofibroblasts and
only a few inflammatory cells. MMP14 is known to be
involved in the activation of proMMP2 by complex
binding to TIMP2.17 In this study, TIMP2 showed higher
expression levels in dilated versus nondilated aortas in
both TAVand BAV patients in the univariate analysis. How-
ever, TIMP2 did not contribute to the group of MMPs and
TIMPs that separated dilated and nondilated aortas into
clusters in the PCA. In addition, TIMP2 expression did
not correlate to maximal aortic diameter. Whether TIMP2
plays a role in MMP14 activation in this study population
is unknown.
In contrast to our results, Ikonimidis and coworkers8 have
shown protein expression of collagenases (MMP1, MMP8,
and MMP13) and MMP7 in aneurysms of the ascending
aorta, and Borges and associates18 have shown that mainlyFIGURE 3. Immunohistochemistry analyses of MMP14 and MMP19 protein e
imens fromTAV patients. A and B,MMP14 staining in dilated (A) and in nondila
factor (endothelial cells) staining, respectively, in consecutive sections of dilat
(320). G-J, Enlargements of MMP19 (G, I) and von Willebrand factor (H, J)
J). K and L, CD68 staining (inflammatory cells) in dilated aorta (K) and a-ac
MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase.
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The Journal of Thoracic and CaMMP7 but also MMP3 are retained in areas of mucoid de-
generation in the ascending aorta of patients with various
TAA etiologies. Furthermore, Koullias and associates19
have shown increased levels of MMP1 and MMP9 protein
expression in patients with TAA (including specimens
from both the ascending and descending aorta as well as
from aneurysms, intramural hemtaomas, and dissections)
in comparison with controls. The discrepancies between
these findings and our results could be attributed to the sen-
sitivity of the exon array analyses used. However, the results
of the real-time PCR analysis confirmed the very low
mRNA expression levels of these MMPs. Importantly,
mRNA expression does not necessarily equal protein ex-
pression and/or enzymatic activity. Also, the mRNA analy-
sis is based on RNA preparations from large parts of the
aorta and local expression cannot be excluded. We analyzed
the aortic tissue with the medial layer separated from the ad-
ventitia inasmuch as it was hypothesized that the adventitial
and medial layers differ in inflammatory profile. However,
the same MMPs were expressed in the adventitia as com-
pared with the intima/media. Another explanation to the
discrepancy between protein and mRNA expression pattern
could be that these proteases are not synthesized in the ves-
sel wall and that their detection is the result of an entrap-
ment of circulating proteases within the aortic wall.
It is possible that decreased expression of MMP17,
MMP21, MMP25, and MMP28 in TAV-related TAA are
markers of dedifferentiation of SMCs/fibroblasts and/or
SMC/myofibroblast apoptosis. MMP21 is structurally
similar toMMP25 and is found invarious tissues and in cells
such as fibroblasts and inflammatory cells.20,21 Interestingly,
lowerMMP21 expression has been suggested as a marker of
dedifferentiated tumor cells.22 Similar to MMP21, MMP28
is downregulated in the setting of malignant tumors.23 An-
other plausible activity of these proteases is their potential
role in apoptosis, a common event associated with the di-
lated aorta.24 However, MMP21 expression was not associ-
ated with apoptosis of tumor cells.25 The exact roles of
MMP21, MMP25, and MMP28 in TAA formation need fur-
ther analyses.
One limitation of the present work is that the study is
heterogeneous, being composed of patients eligible for in-
tervention owing to surgical indications. The cohort thus
varies in gender distribution, valvular disease, surgical
timing, and, owing to the latter, also in aortic size at the
time of surgery. Furthermore, it is known that patientsxpression in the intima/medial layer of dilated and nondilated aortic spec-
ted aorta (B) (320). C and D, Enlargements ofMMP14 and vonWillebrand
ed aorta. E and F, MMP19 staining in dilated (E) and nondilated aorta (F)
staining in consecutive sections of dilated (G, H) and nondilated aorta (I,
tin staining (smooth muscle cells) (L) (320). TAV, Tricuspid aortic valve;
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Swith TAV and BAV present with manifest disease at differ-
ent ages and stages of disease. In addition, possible tempo-
ral differences in gene expression are difficult to study in
human beings, and to the best of our knowledge there are
as yet no adequate animal models available. Taken to-
gether, these factors should be considered in interpreting
the results.
In summary, the present study identifies MMP14 and
MMP19 as proteolytic enzymes potentially involved in
TAA formation in the ascending aorta of TAV patients.
Our findings support the theory that the pathogenesis of
BAV-associated TAA differs from TAV-associated TAA.References
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